Vor Biopharma (VOR) Assets Average (2021 - 2026)

Vor Biopharma (VOR) has 6 years of Assets Average data on file, last reported at $485.4 million in Q1 2026.

• Assets Average for Q1 2026 came in at $485.4 million, up 284.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $485.4 million (up 284.96% YoY), and the FY2025 annual result was $303.5 million, up 78.0% from the prior year.
• Assets Average climbed to $485.4 million in Q1 2026 per VOR's latest filing, from $320.2 million in the prior quarter.
• Over five years, Assets Average peaked at $485.4 million in Q1 2026 and troughed at $126.1 million in Q1 2025.
• A 5-year average of $224.2 million and a median of $215.5 million in 2022 frame the typical range for Assets Average.
• The sharpest annual moves came in 2024 and 2026: Assets Average tumbled 45.66% in 2024, then soared 284.96% in 2026.
• A 5-year view of Assets Average shows it stood at $252.9 million in 2022, then decreased by 16.73% to $210.6 million in 2023, then slumped by 38.53% to $129.4 million in 2024, then soared by 147.36% to $320.2 million in 2025, then soared by 51.61% to $485.4 million in 2026.
• Business Quant data shows VOR's Assets Average at $485.4 million in Q1 2026, $320.2 million in Q4 2025, and $190.8 million in Q3 2025.